

### Clinical Trial Stage

- Entrusts qualified CROs to conduct human clinical trials and ensures that the CROs adopt strict confidentiality measures for the collection, processing, and utilization of subject data.
- Complies with the GDPR, Good Clinical Practice (GCP), “Declaration of Helsinki,” and relevant laws and regulations of various countries, such as Taiwan “Human Research Ethics Policy Guidelines” and “Medical Care Act.”
- The principal investigator of the trial plan must keep the results of the examinee’s examination and the physician’s diagnosis confidential and replace the subjects’ names with numbers. Other forms of privacy protections are required by individual clinical trial hospitals for relevant researchers participating in clinical trials. PEC has no way to identify the personal information of the subjects and has no access to other personal information.

### Post Product Launch

- Conducts Post-Market Surveillance (PMS) before obtaining patient information, we will provide a patient consent form to ensure that we have the patient’s consent and explain to the patient how we handle the information and protect the privacy of the patient.
- Ensure that pharmacists in medical institutions, community pharmacies, and other primary care practices incorporate the concept of privacy protection in their daily practice when providing pharmacy services to the public and medical personnel, and actively protect and ensure that patients’ privacy rights are not violated.

## 2-4 Comprehensive Management of Intellectual Property Rights

PharmaEssentia has formulated the “Intellectual Property Rights Management and Utilization Regulations,” which includes intangible rights and property including patents, trademarks, copyrights, and trade secrets. To make our intellectual property (IP) management system more comprehensive, we are committed to patent application during the product life cycle management, risk control of IP, and new drug IP utilization strategies. Besides closely following the regulations for R&D cycle and complementing the Operational Procedures for Acquisition and Disposal of Assets to protect PEC’s R&D personnel’s intellectual property from infringement, we can also ensure that an innovation becomes PEC’s intellectual property and that our intellectual property can be widely applied for and registered internationally. So that more people in need can know about and have access to the new drugs, and that the IP rights of others will not be infringed upon.

### Management and Statistics of Patents and Trademarks



Known for our innovative R&D competencies, PharmaEssentia applies for types of development patents in line with the R&D progress of each project to plan our global technical strategies. We realized our global intellectual property strategies early on, in as early as our startup period since our product Ropiginterferon alfa-2b (P1101) has realized the goal of applying for multinational regulatory marketing approvals. PEC has obtained patent certifications from around the world; as of 2021, we hold 83 valid patents (9 new patents were added in 2021) from 81 countries (sovereignities); in terms of countries (sovereignities), we have obtained as many as 164 patents. As for trademarks, we have received an additional 19 in 2021, and cumulatively, we hold 96 valid trademarks in 31 countries/regions. In line with the indices from Corporate Governance 3.0 evaluation, PEC’s Intellectual Property department regularly reports annual executions of the Intellectual Property Management Plan, which is correlated with our business objectives, to the Board of Directors on an annual basis. Furthermore, to demonstrate our determination to practice intellectual property management as well as our commitment to intellectual property as a leading new pharmaceutical company, the newly added rules related to intellectual property rights management in the Corporate Governance Best Practice Principles for TWSE/TPEX Listed Companies have also been incorporated into PEC’s internal control procedures. Executions of the Intellectual Property Management Plan in 2021 has been reported to the first Board of Directors meeting convened on March 1, 2022 and have been acknowledged and approved by all Directors.